High baseline fetuin-A levels are associated with lower atherosclerotic plaque progression as measured by 3D ultrasound.
3D ultrasonography
3D, three-dimensional
ABI, ankle-brachial-index
Atherosclerosis
CBVD, cerebrovascular disease
CPP, carotid plaque progression
CPV, carotid plaque volume
CVD, cardiovascular diseases
CVRF, cardiovascular risk factor
FPP, femoral plaque progression
FPV, femoral plaque volume
FRS, Framingham Risk Score
Fetuin A
IMT, intima media thickness
PAD, peripheral arterial disease
PWV, pulse wave velocity
SD, standard deviation
TPP, total plaque progression
TPV, total plaque volume
hsCRP, high sensitivity C-reactive protein
Journal
Atherosclerosis plus
ISSN: 2667-0895
Titre abrégé: Atheroscler Plus
Pays: Netherlands
ID NLM: 9918249514806676
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
11
06
2021
revised:
06
09
2021
accepted:
09
09
2021
entrez:
16
1
2023
pubmed:
21
9
2021
medline:
21
9
2021
Statut:
epublish
Résumé
The glycoprotein fetuin-A has anti-inflammatory effects, increases insulin resistance and plays an important role in calcium metabolism. The aim of our study was to assess the predictive value of fetuin-A on atherosclerotic plaque progression in comparison to the established cardiovascular biomarker high sensitivity C-reactive protein (hsCRP). In this prospective, single center-, cohort study, we included 194 patients with at least one cardiovascular risk factor or established cardiovascular disease (CVD). Over a period of 4 years, each patient underwent 3D plaque volumetry of the carotid and femoral arteries on a yearly basis. To evaluate the predictive value of biomarkers in terms of plaque progression, the baseline values of fetuin-A and hsCRP were correlated with the plaque progression from baseline to the last follow up visit. 171 patients were included in the final analysis. Baseline fetuin-A levels showed a significant negative correlation with plaque progression (r = -0.244; p = 0.001). In contrast, baseline hsCRP levels showed no correlation with plaque progression (r = 0.096, p = 0.20). In the ROC-analysis, fetuin-A had a significantly better predictive value than hsCRP (fetuin-A AUC 0.67; p = 0.001 vs hsCRP AUC 0.49; p = 0.88) with an optimal cut-off value at 712 μg/ml. In patients with high fetuin A levels (>712 μg/ml), a significantly lower plaque progression was observed compared to the group with low fetuin-A levels <712 μg/ml (high fetuin-A 197 mm Higher fetuin-A levels appear to predict lower atherosclerotic plaque progression in patients with or at risk of cardiovascular disease.
Sections du résumé
Background and aims
UNASSIGNED
The glycoprotein fetuin-A has anti-inflammatory effects, increases insulin resistance and plays an important role in calcium metabolism. The aim of our study was to assess the predictive value of fetuin-A on atherosclerotic plaque progression in comparison to the established cardiovascular biomarker high sensitivity C-reactive protein (hsCRP).
Methods
UNASSIGNED
In this prospective, single center-, cohort study, we included 194 patients with at least one cardiovascular risk factor or established cardiovascular disease (CVD). Over a period of 4 years, each patient underwent 3D plaque volumetry of the carotid and femoral arteries on a yearly basis. To evaluate the predictive value of biomarkers in terms of plaque progression, the baseline values of fetuin-A and hsCRP were correlated with the plaque progression from baseline to the last follow up visit.
Results
UNASSIGNED
171 patients were included in the final analysis. Baseline fetuin-A levels showed a significant negative correlation with plaque progression (r = -0.244; p = 0.001). In contrast, baseline hsCRP levels showed no correlation with plaque progression (r = 0.096, p = 0.20). In the ROC-analysis, fetuin-A had a significantly better predictive value than hsCRP (fetuin-A AUC 0.67; p = 0.001 vs hsCRP AUC 0.49; p = 0.88) with an optimal cut-off value at 712 μg/ml. In patients with high fetuin A levels (>712 μg/ml), a significantly lower plaque progression was observed compared to the group with low fetuin-A levels <712 μg/ml (high fetuin-A 197 mm
Conclusions
UNASSIGNED
Higher fetuin-A levels appear to predict lower atherosclerotic plaque progression in patients with or at risk of cardiovascular disease.
Identifiants
pubmed: 36643995
doi: 10.1016/j.athplu.2021.09.001
pii: S2667-0895(21)00032-8
pmc: PMC9833218
doi:
Types de publication
Journal Article
Langues
eng
Pagination
10-17Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
We do not have to report any conflicts of interest.
Références
Eur Heart J. 2016 Aug 1;37(29):2315-2381
pubmed: 27222591
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
Clin Nephrol. 2021 Oct;96(4):199-205
pubmed: 34142946
Atherosclerosis. 2016 Mar;246:344-51
pubmed: 26828753
Am J Cardiol. 2013 Jan 1;111(1):31-7
pubmed: 23062316
Lancet. 2003 Mar 8;361(9360):827-33
pubmed: 12642050
J Clin Med. 2018 Dec 31;8(1):
pubmed: 30602707
J Clin Med. 2019 Nov 21;8(12):
pubmed: 31766373
Hypertens Res. 2013 Feb;36(2):129-33
pubmed: 22972556
Circulation. 2008 Feb 12;117(6):743-53
pubmed: 18212285
Circulation. 2011 Aug 9;124(6):741-5
pubmed: 21824935
Atherosclerosis. 2009 Dec;207(2):341-2
pubmed: 19615685
Clin Endocrinol (Oxf). 2013 May;78(5):712-7
pubmed: 22676641
Cancer Res. 2004 Sep 15;64(18):6402-9
pubmed: 15374947
JAMA. 2007 Mar 28;297(12):1376-8
pubmed: 17384436
Eur J Clin Invest. 2019 May;49(5):e13091
pubmed: 30793296
N Engl J Med. 1999 Jan 14;340(2):115-26
pubmed: 9887164
Kidney Int. 2005 Jun;67(6):2383-92
pubmed: 15882283
JACC Cardiovasc Imaging. 2012 Jul;5(7):681-9
pubmed: 22789936
Stroke. 2006 Jan;37(1):87-92
pubmed: 16339465
J Am Coll Cardiol. 2012 May 8;59(19):1688-96
pubmed: 22554599
Cerebrovasc Dis. 2007;23(1):75-80
pubmed: 17108679
Arterioscler Thromb Vasc Biol. 2017 Nov;37(11):2213-2219
pubmed: 28912366
Circ Res. 2012 Mar 2;110(5):658-62
pubmed: 22383708
Nephrol Dial Transplant. 2005 Aug;20(8):1676-85
pubmed: 15899935
Circulation. 2008 Dec 9;118(24):2555-62
pubmed: 19029462
Kidney Int. 2009 May;75(9):874-6
pubmed: 19367310
J Clin Med. 2020 Aug 31;9(9):
pubmed: 32878068
J Clin Invest. 2003 Aug;112(3):357-66
pubmed: 12897203
Circ Res. 2011 Jun 10;108(12):1494-509
pubmed: 21659653
J Am Heart Assoc. 2014 Jun 24;3(3):e000939
pubmed: 24963103
Hypertens Res. 2013 Feb;36(2):104-6
pubmed: 23034465
J Am Soc Nephrol. 2009 Jun;20(6):1264-74
pubmed: 19389852
J Am Soc Nephrol. 2005 Oct;16(10):2920-30
pubmed: 16093453
Intern Med. 2010;49(13):1281-5
pubmed: 20606360
Diabetes Care. 2013 May;36(5):1222-8
pubmed: 23250801